Evidence map›Paper›PMID 35013322›Full record

ArticleNature communications2022

Overcoming resistance to immune checkpoint therapy in PTEN-null prostate cancer by intermittent anti-PI3Kα/β/δ treatment.

Zhi Qi, Zihan Xu, Liuzhen Zhang, Yongkang Zou, Jinping Li, Wenyu Yan, Cheng Li, Ningshu Liu, Hong Wu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed, 1 pooled it
14.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

67 citing papers in PubMed, 1 synthesis or guideline pooled it, 121 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. NADCell death & disease · 2025
    Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article

7 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Zhi QiThe MOE Key Laboratory of Cell Proliferation and Differentiation, School of Life Sciences, Peking University, Beijing, China.
Zihan XuSchool of Life Sciences, Peking University, Beijing, China.
Liuzhen ZhangThe MOE Key Laboratory of Cell Proliferation and Differentiation, School of Life Sciences, Peking University, Beijing, China.
Yongkang ZouThe MOE Key Laboratory of Cell Proliferation and Differentiation, School of Life Sciences, Peking University, Beijing, China.
Jinping LiThe MOE Key Laboratory of Cell Proliferation and Differentiation, School of Life Sciences, Peking University, Beijing, China.
Wenyu YanThe MOE Key Laboratory of Cell Proliferation and Differentiation, School of Life Sciences, Peking University, Beijing, China.
Cheng LiSchool of Life Sciences, Peking University, Beijing, China.
Ningshu LiuBayer AG, Drug Discovery TRG Oncology, Muellerstrasse 178, 13353, Berlin, Germany.
Hong WuThe MOE Key Laboratory of Cell Proliferation and Differentiation, School of Life Sciences, Peking University, Beijing, China. hongwu@pku.edu.cn.ORCID http://orcid.org/0000-0001-7545-7919
Peking University · CNViva Biotech (China) · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Combining immune checkpoint therapy (ICT) and targeted therapy holds great promises for broad and long-lasting anti-cancer therapies. However, combining ICT with anti-PI3K inhibitors have been challenging because the multifaceted effects of PI3K on both cancer cells and immune cells within the tumor microenvironment. Here we find that intermittent but not daily dosing of a PI3Kα/β/δ inhibitor, BAY1082439, on Pten-null prostate cancer models could overcome ICT resistance and unleash CD8

Indexed as

AnimalsAntibodies, NeutralizingAntineoplastic Agents, Immunologicalbeta 2-MicroglobulinCD8-Positive T-LymphocytesCell Line, TumorCell MovementChemokine CCL5Chemokine CXCL10Class I Phosphatidylinositol 3-KinasesDisease Models, AnimalDrug Resistance, NeoplasmGene Expression Regulation, NeoplasticHumansImmune Checkpoint InhibitorsInterferon-alphaAntibodies, NeutralizingAntineoplastic Agents, Immunologicalbeta 2-MicroglobulinCCL5 protein, humanChemokine CCL5Chemokine CXCL10Class I Phosphatidylinositol 3-KinasesCXCL10 protein, humanImmune Checkpoint InhibitorsInterferon-alphaInterferon-gammaPdcd1 protein, mousePik3ca protein, mouseProgrammed Cell Death 1 ReceptorPTEN PhosphohydrolasePten protein, mouse

Identifiers

PMID35013322
PMCPMC8748754
OpenAlexW4205294617

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.